Cara Therapeutics (Nasdaq:CARA) is a clinical-stage biopharmaceutical company which also focuses on pain medication. It has a market cap of $455 million, and is not profitable. Guest Devin Shutte from The Robert Group and resident expert Paul Theron from Vestact decide whether Cara Therapeutics is hot or not.